Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
SOURCE – Tyra Biosciences, Inc. – In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein– -TYRA remains on track to submit ACH Investigational…